Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial.
Séverine VermeireChinyu SuNervin LawendyTaku KobayashiWilliam J SandbornDavid T RubinIrene ModestoSean GardinerNicole KulisekHaiying ZhangWenjin WangJulian PanésPublished in: Journal of Crohn's & colitis (2021)
Most patients in stable remission on 10 mg BID maintenance therapy maintained remission following dose de-escalation. For patients who dose de-escalated, those in deep endoscopic remission and those without prior TNFi failure were more likely to maintain remission. Efficacy data were limited to the first 6 months; a longer duration of follow-up during RIVETING will further characterise the impact of dose reduction on maintenance of remission. Safety findings were consistent with the established safety profile of tofacitinib.
Keyphrases
- ulcerative colitis
- disease activity
- rheumatoid arthritis
- clinical trial
- end stage renal disease
- open label
- study protocol
- ejection fraction
- systemic lupus erythematosus
- newly diagnosed
- type diabetes
- chronic kidney disease
- randomized controlled trial
- stem cells
- bone marrow
- electronic health record
- peritoneal dialysis
- phase iii
- weight loss
- smoking cessation
- patient reported
- glycemic control